Factors to Consider When Switching Therapies

Author(s):

Kirollos Hanna, PharmD, BCPS, BCOPBrandon Dyson, PharmD, BCPS

The discussion covers when to consider transitioning to a new therapeutic option in CLL and the factors that influence the decision between dose modification and switching therapies.

EP: 1.BTK Inhibitor-Associated Adverse Events

EP: 2.Managing Adverse Events and Supportive Care Measures in CLL Treatment

EP: 3.Impact of Dose Modifications on CLL Treatment

EP: 4.Considerations for Dose Modifications

EP: 5.Economic Impact of Dose Modifications on CLL Management

Now Viewing

EP: 6.Factors to Consider When Switching Therapies

EP: 7.Medicare Part D Smoothing Program: Impact on Access and Adherence

Video content above is prompted by the following:

When is transitioning to a new therapeutic option considered, and what factors influence the decision between dose modification and switching therapies in chronic lymphocytic leukemia treatment?